Ugur Selek

Prof. Dr. Ugur Selek

Koç University, Istanbul, İstanbul, Turkey (Türkiye)
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2012 in The Lancet Oncology
Verified
Journal Article
Open access
XWXin Shelley Wang
Xin Shelley Wang
LRLaurence Rhines
Laurence Rhines
ASAlmon S Shiu
Almon S Shiu
JYJames N Yang
James N Yang
USUgur Selek
Ugur Selek
ECEric L Chang
Eric L Chang
Spinal stereotactic body radiation therapy (SBRT) is increasingly used to manage spinal metastases, yet the technique's effectiveness in controlling the symptom burden of spinal metastases has not been well described. We investigated the clinical benefit of SBRT for managing spinal metastases and reducing cancer-related symptoms. 149 patients with mechanically stable, non-cord-compressing spinal metastases (166 lesions) were given SBRT in a phase 1-2 study. Patients received a total dose of 27-30 Gy, typically in three fractions. Symptoms were measured before SBRT and at several time points up to 6 months after treatment, by the Brief Pain Inventory (BPI) and the M D Anderson Symptom Inventory (MDASI). The primary endpoint was frequency and duration of complete pain relief. The study is completed and is registered with ClinicalTrials.gov, number NCT00508443. Median follow-up was 15·9 months (IQR 9·5-30·3). The number of patients reporting no pain from bone metastases, as measured by the BPI, increased from 39 of 149 (26%) before SBRT to 55 of 102 (54%) 6 months after SBRT (p<0·0001). BPI-reported pain reduction from baseline to 4 weeks after SBRT was clinically meaningful (mean 3·4 [SD 2·9] on the BPI pain-at-its-worst item at baseline, 2·1 [2·4] at 4 weeks; effect size 0·47, p=0·00076). These improvements were accompanied by significant reduction in opioid use during the first 6 months after SBRT (43 [28·9%] of 149 patients with strong opioid use at baseline vs 20 [20·0%] of 100 at 6 months; p=0·011). Ordinal regression modelling showed that patients reported significant pain reduction according to the MDASI during the first 6 months after SBRT (p=0·00003), and significant reductions in a composite score of the six MDASI symptom interference with daily life items (p=0·0066). Only a few instances of non-neurological grade 3 toxicities occurred: nausea (one event), vomiting (one), diarrhoea (one), fatigue (one), dysphagia (one), neck pain (one), and diaphoresis (one); pain associated with severe tongue oedema and trismus occurred twice; and non-cardiac chest pain was reported three times. No grade 4 toxicities occurred. Progression-free survival after SBRT was 80·5% (95% CI 72·9-86·1) at 1 year and 72·4% (63·1-79·7) at 2 years. SBRT is an effective primary or salvage treatment for mechanically stable spinal metastasis. Significant reductions in patient-reported pain and other symptoms were evident 6 months after SBRT, along with satisfactory progression-free survival and no late spinal cord toxicities. National Cancer Institute of the US National Institutes of Health.

29 October 2004 in Cancer
Verified
Journal Article
Open access
PDF file
DRDavid I. Rosenthal
David I. Rosenthal
JBJerry L. Barker
Jerry L. Barker
AEAdel K. El‐Naggar
Adel K. El‐Naggar
BGBonnie S. Glisson
Bonnie S. Glisson
MKMerrill S. Kies
Merrill S. Kies
AGAdam S. Garden
Adam S. Garden
BACKGROUND: Sinonasal neuroendocrine tumors are rare malignancies that are represented by a spectrum of histologies, including esthesioneuroblastoma (ENB), sinonasal undifferentiated carcinoma (SNUC), neuroendocrine carcinoma (NEC), and small cell carcinoma (SmCC). The authors reviewed their institutional experience to determine whether sinonasal neuroendocrine tumors of different histologies have distinct clinical characteristics that warrant individualized treatment approaches.METHODS: The authors treated 72 adults with pathologically proven, nonmetastatic, primary sinonasal neuroendocrine tumors from 1982 to 2002. There were 31 patients with ENB, 16 patients with SNUC, 18 patients with NEC, and 7 patients with SmCC. Patients with ENB usually were treated with local therapy alone (surgery and/or radiotherapy); only 3 of 31 patients (9.7%) received treatment (radiation) to regional lymphatics, and only 5 of 31 patients (16.1%) received chemotherapy. In contrast, patients with non‐ENB histologies usually received chemotherapy (10 of 16 patients with SNUC, 12 of 18 patients with NEC, and 5 of 7 patients with SmCC), and nonsurgical locoregional therapy was used more frequently (6 of 16 patients with SNUC, 4 of 18 patients with NEC, and 5 of 7 patients with SmCC).RESULTS: The median follow‐up for surviving patients was 81.5 months (range, 6–266 months). The Kaplan–Meier estimate of overall survival at 5 years was 93.1% for patients with ENB, 62.5% for patients with SNUC, 64.2% for patients with NEC, and 28.6% for patients with SmCC (P = 0.0029; log‐rank test). The local control rate at 5 years also was superior for patients who had ENB (96.2%) compared with patients who had SNUC (78.6%), NEC (72.6%), or SmCC (66.7%) (P = 0.04). The regional failure (RF) rate at 5 years was 8.7% for patients with ENB, 15.6% for patients with SNUC, 12.9% for patients with NEC, and 44.4% for patients with SmCC. Additional late events increased the RF rate for patients with ENB to 31.9% at 10 years. The distant metastasis rate at 5 years was 0.0% for patients with ENB, 25.4% for patients with SNUC, 14.1% for patients with NEC, and 75.0% for patients with SmCC.CONCLUSIONS: This spectrum of malignancies with neuroendocrine features shares a common site of origin within the head and neck, but their natural histories appear to diverge into two main groups: ENB and non‐ENB. Patients with ENB had excellent local and distant control rates with local therapy alone. Given the higher rates of systemic failure for patients with SNUC, NEC, and SmCC, the authors favor the use of combined‐modality therapy for these patients. Cancer 2004. © 2004 American Cancer Society.

15 February 2019 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
HMHari Menon
Hari Menon
RRRishab Ramapriyan
Rishab Ramapriyan
TCTaylor R. Cushman
Taylor R. Cushman
VVVivek Verma
Vivek Verma
HKHans H. Kim
Hans H. Kim
JWJames W. Welsh
James W. Welsh
In recent decades, there has been substantial growth in our understanding of the immune system and its role in tumor growth and overall survival. A central finding has been the cross-talk between tumor cells and the surrounding environment or stroma. This tumor stroma, comprised of various cells, and extracellular matrix (ECM), has been shown to aid in suppressing host immune responses against tumor cells. Through immunosuppressive cytokine secretion, metabolic alterations, and other mechanisms, the tumor stroma provides a complex network of safeguards for tumor proliferation. With recent advances in more effective, localized treatment, radiation therapy (XRT) has allowed for strategies that can effectively alter and ablate tumor stromal tissue. This includes promoting immunogenic cell death through tumor antigen release to increasing immune cell trafficking, XRT has a unique advantage against the tumoral immune evasion mechanisms that are orchestrated by stromal cells. Current studies are underway to elucidate pathways within the tumor stroma as potential targets for immunotherapy and chemoradiation. This review summarizes the effects of tumor stroma in tumor immune evasion, explains how XRT may help overcome these effects, with potential combinatorial approaches for future treatment modalities.

20 February 2004 in Cancer
Verified
Journal Article
Open access
PDF file
SSSerdar Soyuer
Serdar Soyuer
ECEric L. Chang
Eric L. Chang
USUgur Selek
Ugur Selek
IMIan E. McCutcheon
Ian E. McCutcheon
MMMoshe H. Maor
Moshe H. Maor
BACKGROUND: The current retrospective study was undertaken to evaluate the treatment outcomes of patients with meningeal hemangiopericytoma (M‐HPC), to define the role of radiotherapy in the management of the disease, and to report on the patterns of failure.METHODS: The medical records of 29 patients with nonmetastatic M‐HPC treated at The University of Texas M. D. Anderson Cancer Center (Houston, TX) between August 1979 and March 1999 were reviewed. Fifteen patients (52%) underwent macroscopic total resection (‘gross total resection’ [GTR]), 10 (34%) underwent subtotal resection (STR), and 4 (14%) had unknown extent of surgery. Ten of 24 patients received adjuvant radiotherapy.RESULTS: The 5, 10, and 15‐year overall survival rates were 85%, 68%, and 43%, respectively. The local control rates at 5 and 10 years were 68% and 22%, respectively. Two patients experienced disease recurrence at another intracranial site. Sixteen patients (55%) developed extraneural metastases. Four patients (14%) developed spinal metastases. The 5‐, 10‐, and 15‐year distant metastasis–free survival rates were 80%, 46%, and 21%, respectively. The 5‐year local control rates for patients treated with GTR and STR were 84% and 38%, respectively (P = 0.003). Of the 15 patients treated with GTR, 3 received adjuvant radiotherapy as part of their initial treatment. Malignant disease did not recur locally in these three patients. However, the effect of the adjuvant radiotherapy on local control was not statistically significant.CONCLUSIONS: M‐HPCs can recur locally or distantly in the neural axis or as extraneural distant metastases. Based on literature review and the patterns of failure in the current series, attempting to perform GTR followed by limited‐field radiotherapy appeared to represent a reasonable approach for the initial management of M‐HPC. Cancer 2004;100:1491–7. © 2004 American Cancer Society.

1 July 2004 in International Journal of Radiation Oncology - Biology - Physics (IJROBP)
Verified
Journal Article
Closed access
USUgur Selek
Ugur Selek
ECEric L. Chang
Eric L. Chang
SHSamuel J. Hassenbusch
Samuel J. Hassenbusch
ASAlmon S. Shiu
Almon S. Shiu
FLFrederick F. Lang
Frederick F. Lang
MMMoshe H. Maor
Moshe H. Maor

1 April 2004 in Radiotherapy and Oncology
Verified
Journal Article
Closed access
SSSerdar Soyuer
Serdar Soyuer
ECEric L Chang
Eric L Chang
USUgur Selek
Ugur Selek
WSWeiming Shi
Weiming Shi
MMMoshe H Maor
Moshe H Maor
FDFranco DeMonte
Franco DeMonte